tirzepatide patent challenge How Paragraph IV Challenges Actually Work: The $200B Generic Drug Playbook How to Survive the GLP-1 BPI challenges Eli Lilly's patent

In addition, semaglutide-induced restoration of circulating NK cell cytokine production has recently been proposed as a GLP1R-dependent immune regulatory mechanism improving metabolic outcomes in obesity and reduce cancer risk 92

Despite advances in surgical techniques, chemoradiotherapy, targeted agents, and immunotherapies that have improved outcomes for some patients, intratumoural heterogeneity and adaptive resistance continue to limit durable responses in many cases [3]

While international growth and the launch of oral Wegovy offer some support, increased costs and lack of one-off benefits limit upside, leaving investors doubtful about NVOs ability to sustain its leadership in the evolving obesity market

Mayszczak, A., Przedziecka-Doyk, J., Szydeko-Pako, U